Pharmacological therapy using type-1 bioactive compounds in OI treatment stimulate collagen biosynthesis by increasing prolidase activity and is accompanied by increased IGF-I receptor expression (Galicka and Nazaruk, 2007). Here, IGF1R is linked to osteogenesis imperfecta.